Literature DB >> 2868658

Antihypertensive therapy and lipids. Paradoxical influences on cardiovascular disease risk.

M H Weinberger.   

Abstract

It is generally acknowledged that hypertension is associated with an increased risk of cardiovascular morbidity and mortality, and that lowering elevated blood pressure is effective in reducing that risk. However, hypertension is more likely to cause cardiovascular disease in those with additional risk factors, such as cigarette smoking, hyperlipidemia, diabetes mellitus, hypokalemia, loft ventricular hypertrophy, or electrocardiographic abnormalities. The evidence to date indicates that not all patients with mild hypertension need to be treated with drugs; not all of those receiving drug therapy should be treated with the same drugs; and the benefit of the same degree of reduction in blood pressure may not be equivalent for different drugs. The use of traditional step 1 diuretic therapy is not uniformly appropriate. As an alternative, the vasodilator prazosin can be effective as monotherapy in the treatment of mild hypertension, and its addition to diuretic or beta blocker therapy appears to blunt or prevent the adverse effects of those agents on lipid levels. Since prazosin therapy is least likely to worsen existing risk factors or precipitate their occurrence, it should enhance the benefit of blood pressure reduction in delaying or preventing cardiovascular disease.

Entities:  

Mesh:

Substances:

Year:  1986        PMID: 2868658     DOI: 10.1016/0002-9343(86)90162-2

Source DB:  PubMed          Journal:  Am J Med        ISSN: 0002-9343            Impact factor:   4.965


  16 in total

1.  A comparison of diltiazem and metoprolol in hypertension. Swedish Diltiazem-Metoprolol Multicentre Study Group.

Authors:  T Hedner; T Thulin; S Gustafsson; S O Olsson
Journal:  Eur J Clin Pharmacol       Date:  1990       Impact factor: 2.953

Review 2.  Reserpine: a relic from the past or a neglected drug of the present for achieving cost containment in treating hypertension?

Authors:  G J Magarian
Journal:  J Gen Intern Med       Date:  1991 Nov-Dec       Impact factor: 5.128

3.  Effects of beta-blockers on HMG CoA reductase and LDL receptor activity in cultured human skin fibroblasts.

Authors:  H Yoshida; M Suzukawa; T Ishikawa; H Shige; E Nishio; H Hosoai; M Ayaori; H Nakamura
Journal:  Cardiovasc Drugs Ther       Date:  1996-03       Impact factor: 3.727

Review 4.  A woman's heart. An update of coronary artery disease risk in women.

Authors:  D A Leaf
Journal:  West J Med       Date:  1988-12

Review 5.  Profile of an ideal antianginal agent.

Authors:  E J Lazar; W H Frishman
Journal:  Drugs       Date:  1989       Impact factor: 9.546

6.  Antihypertensive therapy, serum lipids, coronary heart disease and hypertension--balancing the risks and benefits of treatment.

Authors:  M C Houston
Journal:  West J Med       Date:  1986-08

7.  Effects of dicentrine on haemodynamic, plasma lipid, lipoprotein level and vascular reactivity in hyperlipidaemic rats.

Authors:  S M Yu; Y F Kang; C C Chen; C M Teng
Journal:  Br J Pharmacol       Date:  1993-04       Impact factor: 8.739

8.  Diabetes mellitus and raised serum triglyceride concentration in treated hypertension--are they of prognostic importance? Observational study.

Authors:  O Samuelsson; K Pennert; O Andersson; G Berglund; T Hedner; B Persson; H Wedel; L Wilhelmsen
Journal:  BMJ       Date:  1996-09-14

9.  Lipid and apolipoprotein levels during therapy with pinacidil combined with hydrochlorothiazide.

Authors:  C N Corder; M R Goldberg; P A Alaupovic; M D Price; S S Furste
Journal:  Eur J Clin Pharmacol       Date:  1992       Impact factor: 2.953

10.  Selective screening for high cholesterol in Australian general practice: the Newcastle Cholesterol Prediction Study.

Authors:  S Kinlay; R F Heller
Journal:  J Gen Intern Med       Date:  1990 Jan-Feb       Impact factor: 5.128

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.